News & Events
BioLamina and Axion BioSystems partner to advance organoid research for disease modeling and therapeutic discovery
Stockholm, Sweden, and Atlanta, U.S., 19 August 2026 BioLamina and Axion BioSystems partner to advance organoid research for disease modeling […]
BioLamina appoints Sofia Helgesson as Chief Financial Officer
Stockholm, Sweden 12 August 2026 BioLamina appoints Sofia Helgesson as Chief Financial Officer We are delighted to welcome Sofia Helgesson as BioL […]
BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned with FDA Moderniziation Act 2.0
Stockholm, Sweden and Edinburgh, UK, 28 May 2026 BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned […]
-
Publications September 4, 2026
The role of laminin α5 in extracellular matrix organization during human chondrogenesis
Human skeletal development depends not only on the differentiation of cartilage-forming cells, but also on their organization within the developing […]
-
Publications August 28, 2026
Maintaining stable transgene expression during stem cell differentiation
Human pluripotent stem cells (hPSCs) have become indispensable tools for studying development, modeling disease, and evaluating new therapeutics. Ma […]
-
Publications August 21, 2026
Developing tissue-specific extracellular matrices for regenerative medicine
Three-dimensional (3D) stem cell culture systems play an essential role in tissue engineering and regenerative medicine by recreating the cellular i […]
-
Featured August 19, 2026
BioLamina and Axion BioSystems partner to advance organoid research for disease modeling and therapeutic discovery
Stockholm, Sweden, and Atlanta, U.S., 19 August 2026 BioLamina and Axion BioSystems partner to advance organoid research for disease modeling […]
-
Publications August 17, 2026
Supporting large-scale drug discovery with patient-derived motor neurons
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the loss of motor neurons, leading to muscle weaknes […]
-
Featured August 12, 2026
BioLamina appoints Sofia Helgesson as Chief Financial Officer
Stockholm, Sweden 12 August 2026 BioLamina appoints Sofia Helgesson as Chief Financial Officer We are delighted to welcome Sofia Helgesson as BioL […]
-
Publications July 17, 2026
Recreating human hypothalamic development using defined Biolaminin® substrates
The hypothalamus is the central control center for appetite and energy balance, integrating hormonal signals that regulate food intake and metabolis […]
-
Publications July 14, 2026
Engineering physiologically relevant renal epithelial models through basement membrane mimicry
Human renal proximal tubular epithelial cells (RPTECs) are widely used as in vitro models for studying kidney biology and supporting the development […]
-
Publications July 14, 2026
Coordinated extracellular matrix signaling regulates local translation during axon guidance
During the development of the nervous system, growing axons rely on specialized structures known as growth cones to navigate toward their correct […]
-
Publications July 2, 2026
New insights into astrocyte maturation during spinal cord development
The spinal cord is composed of both gray and white matter, with white matter containing axonal tracts responsible for transmitting sensory and […]
-
Publications July 2, 2026
Animal component-free macrophage differentiation using Biolaminin® 521
Macrophages are essential immune cells that play central roles in maintaining tissue health and coordinating inflammatory responses. Because of thes […]
-
Publications July 2, 2026
Efficient generation of highly purified pancreatic islets across multiple stem cell lines
Human pluripotent stem cell (hPSC)-derived pancreatic islets show significant promise for cell replacement therapies in type 1 diabetes, but the cur […]
-
Publications June 26, 2026
Advancing stem cell-derived liver implants toward clinical translation using defined Biolaminin® matrices
This study highlights the importance of chemically defined extracellular matrix environments for translating stem cell-derived tissue engineering te […]
-
Featured May 28, 2026
BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned with FDA Moderniziation Act 2.0
Stockholm, Sweden and Edinburgh, UK, 28 May 2026 BioLamina and Cytochroma partner to accelerate reliable New Approach Methodologies aligned […]
-
Featured April 17, 2026
Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB commitment
Sundbyberg, April 16, 2026 Swedish company BioLamina to enable next-generation cell therapies for serious chronic diseases with €20 million EIB co […]
-
Publications February 2, 2026
Biolaminin 521 supports animal origin-free hESC-RPE differentiation and retinal rescue
This study demonstrates that combining a fully defined, animal origin-free culture medium with a physiologically relevant extracellular matrix is ke […]